Asunto(s)
Dermatosis Facial/diagnóstico , Hipopigmentación/diagnóstico , Cuello , Neoplasias de Anexos y Apéndices de Piel/diagnóstico , Neoplasias de Anexos y Apéndices de Piel/patología , Neoplasias Cutáneas/diagnóstico , Adulto , Biopsia , Diagnóstico Diferencial , Dermatosis Facial/patología , Humanos , Hipopigmentación/patología , Masculino , Piel/patología , Neoplasias Cutáneas/patologíaAsunto(s)
Inhibidores de la Angiogénesis/efectos adversos , Cicatriz/patología , Neoplasias Colorrectales/tratamiento farmacológico , Proteínas Recombinantes de Fusión/efectos adversos , Úlcera Cutánea/inducido químicamente , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Abdomen , Inhibidores de la Angiogénesis/uso terapéutico , Vendajes , Neoplasias Colorrectales/cirugía , Humanos , Masculino , Persona de Mediana Edad , Necrosis/inducido químicamente , Receptores de Factores de Crecimiento Endotelial Vascular/uso terapéutico , Proteínas Recombinantes de Fusión/uso terapéutico , Recurrencia , Remisión Espontánea , Úlcera Cutánea/patología , Úlcera Cutánea/terapia , Privación de TratamientoRESUMEN
Locoregional cutaneous metastases of melanoma (LCMM) represent a therapeutic challenge. Many treatment options are available with varying results. The combination of cryotherapy and imiquimod, two treatments with a possible synergistic effect, has not yet been described for treating this disease. In this paper, we aimed to show the response of LCMM to cryotherapy combined with topical imiquimod 5%. A retrospective review of 20 patients diagnosed with LCMM and treated with cryotherapy combined with topical imiquimod 5% between November 2000 and May 2014 at three institutions was performed. The locoregional cutaneous response was evaluated. After a mean of five sessions, 13 patients (65%) responded to treatment, eight (40%) of these completely and five (25%) partially. Systemic disease progressed in 16 (80%) patients. Cryotherapy followed by topical imiquimod 5% is simple to apply, has minimal adverse effects and provides response rates similar to other, more complex treatment options.
Asunto(s)
Aminoquinolinas/uso terapéutico , Antineoplásicos/uso terapéutico , Criocirugía , Melanoma/terapia , Neoplasias Cutáneas/terapia , Administración Cutánea , Anciano , Anciano de 80 o más Años , Aminoquinolinas/administración & dosificación , Antineoplásicos/administración & dosificación , Terapia Combinada , Femenino , Humanos , Imiquimod , Masculino , Melanoma/tratamiento farmacológico , Melanoma/patología , Melanoma/cirugía , Persona de Mediana Edad , Metástasis de la Neoplasia , Estudios Retrospectivos , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patología , Neoplasias Cutáneas/cirugíaRESUMEN
BACKGROUND: Treatment of oral erosive lichen planus is considered a therapeutic challenge. Various systemic and topical agents aimed at controlling the symptoms, rather than curing the lesions, have been used with varying results. OBJECTIVE: To evaluate the response to treatment with antimalarial drugs in patients with oral erosive lichen planus. METHODS: Eight patients diagnosed with oral erosive lichen planus were treated with antimalarial agents. The first clinical evaluation was made after a month of treatment and then every 2-3 months. Baseline ophthalmologic examinations were performed, and laboratory values were monitored before and during treatment. RESULTS: All studied patients who had previously been resistant to other treatments responded favorably. Pain relief and reduced erythema and erosions were observed after of a mean of 2.4 months. CONCLUSION: Antimalarials may be useful for the treatment of oral erosive lichen planus. They are easily administered and affordable, with few adverse effects.
